drugset / Trial / NCT00945295

Efficacy and Safety Study of Botulinum Neurotoxin A With Rehabilitation Versus Botulinum Neurotoxin A Alone in Treatment of Post-stroke Spasticity

NCT00945295

Completed 31 enrolled JoAnn Harnar Allergan · collab
RandomizedParallel-groupOpen-labelTreatment

Summary

The purpose of this study is to determine if a combination of botulinum neurotoxin A and rehabilitation therapy is better than botulinum neurotoxin A alone for improvement in function based on the Fugl-Meyer and other validated measures. Hypothesis: The combination of botulinum neurotoxin A and rehabilitation therapy will produce better functional improvement than botulinum neurotoxin A alone in post-stroke upper limb spasticity measured by the Fugl-Meyer Assessment of Sensorimotor Recovery after Stroke.

Timeline

Start
2009-01
Primary completion
2012-05
Completion
2012-05

Drugs

EvaluationDrugModalityDoseRoute
Comparator Botulinum toxin type A Protein / enzyme biologic 6 iu/kg Intramuscular
Comparator Botulinum toxin type A Protein / enzyme biologic 200 iu Intramuscular
Comparator Botulinum toxin type A Protein / enzyme biologic 400 iu Intramuscular

Indications

No indication recorded.